MEDIORG Stock Overview
Engages in the developing, manufacturing, and distribution of a range of pharmaceutical dosage in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Medicamen Organics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹56.30 |
| 52 Week High | ₹159.40 |
| 52 Week Low | ₹47.00 |
| Beta | 0 |
| 1 Month Change | 11.71% |
| 3 Month Change | -14.70% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDIORG | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.9% | 0.8% | -4.2% |
| 1Y | n/a | 39.7% | 19.1% |
Return vs Industry: Insufficient data to determine how MEDIORG performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MEDIORG performed against the Indian Market.
Price Volatility
| MEDIORG volatility | |
|---|---|
| MEDIORG Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: MEDIORG has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: Insufficient data to determine MEDIORG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 62 | Bal Gupta | www.medicamenorganics.com |
Medicamen Organics Limited engages in the developing, manufacturing, and distribution of a range of pharmaceutical dosage in India and internationally. The company offers anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental cure, proton pump inhibitor, anti-protozoal, anti-histamine, anti-hypertensive, anti-lipidemic, anti-parasitic, multivitamin, multimineral, and non-steroidal anti-inflammatory drugs in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. It markets its products to for government and private institutions as contract manufacturer/third party manufacturer; and private pharma companies through third party distributors.
Medicamen Organics Limited Fundamentals Summary
| MEDIORG fundamental statistics | |
|---|---|
| Market cap | ₹658.71m |
| Earnings (TTM) | ₹25.52m |
| Revenue (TTM) | ₹308.02m |
25.8x
P/E Ratio2.1x
P/S RatioIs MEDIORG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDIORG income statement (TTM) | |
|---|---|
| Revenue | ₹308.02m |
| Cost of Revenue | ₹206.75m |
| Gross Profit | ₹101.27m |
| Other Expenses | ₹75.75m |
| Earnings | ₹25.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.18 |
| Gross Margin | 32.88% |
| Net Profit Margin | 8.29% |
| Debt/Equity Ratio | 47.1% |
How did MEDIORG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 11:29 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medicamen Organics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|